The global market for Chronic Granulomatous Disease (CGD) Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Chronic Granulomatous Disease (CGD) Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Chronic Granulomatous Disease (CGD) Treatment by region & country, by Type, and by Application.

The Chronic Granulomatous Disease (CGD) Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Granulomatous Disease (CGD) Treatment.

Market Segmentation

Scope of Chronic Granulomatous Disease (CGD) Treatment - Market Report

Report Metric	Details
Report Name	Chronic Granulomatous Disease (CGD) Treatment - Market
CAGR	5%
Segment by Type:	X-Linked Chronic Granulomatous Disease Autosomal Recessive Chronic Granulomatous Disease
Segment by Application	Neutrophil Function Tests Genetic Testing Prenatal Testing
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc, Merck KGaA
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Chronic Granulomatous Disease (CGD) Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Chronic Granulomatous Disease (CGD) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Chronic Granulomatous Disease (CGD) Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Chronic Granulomatous Disease (CGD) Treatment - Market report?

Ans: The main players in the Chronic Granulomatous Disease (CGD) Treatment - Market are Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc, Merck KGaA

What are the Application segmentation covered in the Chronic Granulomatous Disease (CGD) Treatment - Market report?

Ans: The Applications covered in the Chronic Granulomatous Disease (CGD) Treatment - Market report are Neutrophil Function Tests, Genetic Testing, Prenatal Testing

What are the Type segmentation covered in the Chronic Granulomatous Disease (CGD) Treatment - Market report?

Ans: The Types covered in the Chronic Granulomatous Disease (CGD) Treatment - Market report are X-Linked Chronic Granulomatous Disease, Autosomal Recessive Chronic Granulomatous Disease

1 Market Overview

1.1 Chronic Granulomatous Disease (CGD) Treatment Product Introduction

1.2 Global Chronic Granulomatous Disease (CGD) Treatment Market Size Forecast

1.3 Chronic Granulomatous Disease (CGD) Treatment Market Trends & Drivers

1.3.1 Chronic Granulomatous Disease (CGD) Treatment Industry Trends

1.3.2 Chronic Granulomatous Disease (CGD) Treatment Market Drivers & Opportunity

1.3.3 Chronic Granulomatous Disease (CGD) Treatment Market Challenges

1.3.4 Chronic Granulomatous Disease (CGD) Treatment Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Chronic Granulomatous Disease (CGD) Treatment Players Revenue Ranking (2023)

2.2 Global Chronic Granulomatous Disease (CGD) Treatment Revenue by Company (2019-2024)

2.3 Key Companies Chronic Granulomatous Disease (CGD) Treatment Manufacturing Base Distribution and Headquarters

2.4 Key Companies Chronic Granulomatous Disease (CGD) Treatment Product Offered

2.5 Key Companies Time to Begin Mass Production of Chronic Granulomatous Disease (CGD) Treatment

2.6 Chronic Granulomatous Disease (CGD) Treatment Market Competitive Analysis

2.6.1 Chronic Granulomatous Disease (CGD) Treatment Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Chronic Granulomatous Disease (CGD) Treatment Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Treatment as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 X-Linked Chronic Granulomatous Disease

3.1.2 Autosomal Recessive Chronic Granulomatous Disease

3.2 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type

3.2.1 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value, by Type (2019-2030)

3.2.3 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Neutrophil Function Tests

4.1.2 Genetic Testing

4.1.3 Prenatal Testing

4.2 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application

4.2.1 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value, by Application (2019-2030)

4.2.3 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region

5.1.1 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region (2019-2024)

5.1.3 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region (2025-2030)

5.1.4 Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

5.2.2 North America Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

5.3.2 Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

5.4.2 Asia Pacific Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

5.5.2 South America Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

5.6.2 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Chronic Granulomatous Disease (CGD) Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Chronic Granulomatous Disease (CGD) Treatment Sales Value

6.3 United States

6.3.1 United States Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

6.3.2 United States Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

6.4.2 Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

6.5.2 China Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

6.5.3 China Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

6.6.2 Japan Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

6.7.2 South Korea Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

6.8.2 Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019-2030

6.9.2 India Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

6.9.3 India Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Clinigen Group plc

7.1.1 Clinigen Group plc Profile

7.1.2 Clinigen Group plc Main Business

7.1.3 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.1.4 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.1.5 Clinigen Group plc Recent Developments

7.2 Orchard Therapeutics plc2032

7.2.1 Orchard Therapeutics plc2032 Profile

7.2.2 Orchard Therapeutics plc2032 Main Business

7.2.3 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.2.4 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.2.5 Orchard Therapeutics plc2032 Recent Developments

7.3 Horizon Therapeutics plc

7.3.1 Horizon Therapeutics plc Profile

7.3.2 Horizon Therapeutics plc Main Business

7.3.3 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.3.4 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.3.5 ViroMed. Co. Ltd Recent Developments

7.4 ViroMed. Co. Ltd

7.4.1 ViroMed. Co. Ltd Profile

7.4.2 ViroMed. Co. Ltd Main Business

7.4.3 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.4.4 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.4.5 ViroMed. Co. Ltd Recent Developments

7.5 Bellicum Pharmaceuticals, Inc

7.5.1 Bellicum Pharmaceuticals, Inc Profile

7.5.2 Bellicum Pharmaceuticals, Inc Main Business

7.5.3 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.5.4 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.5.5 Bellicum Pharmaceuticals, Inc Recent Developments

7.6 Pfizer Inc

7.6.1 Pfizer Inc Profile

7.6.2 Pfizer Inc Main Business

7.6.3 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.6.4 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.6.5 Pfizer Inc Recent Developments

7.7 Hoffmann-La Roche Ltd

7.7.1 Hoffmann-La Roche Ltd Profile

7.7.2 Hoffmann-La Roche Ltd Main Business

7.7.3 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.7.4 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.7.5 Hoffmann-La Roche Ltd Recent Developments

7.8 Novartis AG

7.8.1 Novartis AG Profile

7.8.2 Novartis AG Main Business

7.8.3 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.8.4 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.8.5 Novartis AG Recent Developments

7.9 Lonza

7.9.1 Lonza Profile

7.9.2 Lonza Main Business

7.9.3 Lonza Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.9.4 Lonza Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.9.5 Lonza Recent Developments

7.10 GlaxoSmithKline plc

7.10.1 GlaxoSmithKline plc Profile

7.10.2 GlaxoSmithKline plc Main Business

7.10.3 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.10.4 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.10.5 GlaxoSmithKline plc Recent Developments

7.11 Eli Lilly and Company

7.11.1 Eli Lilly and Company Profile

7.11.2 Eli Lilly and Company Main Business

7.11.3 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.11.4 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.11.5 Eli Lilly and Company Recent Developments

7.12 Johnson & Johnson Services, Inc

7.12.1 Johnson & Johnson Services, Inc Profile

7.12.2 Johnson & Johnson Services, Inc Main Business

7.12.3 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.12.4 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.12.5 Johnson & Johnson Services, Inc Recent Developments

7.13 Merck KGaA

7.13.1 Merck KGaA Profile

7.13.2 Merck KGaA Main Business

7.13.3 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

7.13.4 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Revenue (US$ Million) & (2019-2024)

7.13.5 Merck KGaA Recent Developments

8 Industry Chain Analysis

8.1 Chronic Granulomatous Disease (CGD) Treatment Industrial Chain

8.2 Chronic Granulomatous Disease (CGD) Treatment Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Chronic Granulomatous Disease (CGD) Treatment Sales Model

8.5.2 Sales Channel

8.5.3 Chronic Granulomatous Disease (CGD) Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Clinigen Group PLC

Orchard Therapeutics plc2032

Horizon Therapeutics plc

ViroMed

Bellicum Pharmaceuticals Inc

Pfizer Inc

Hoffmann-La Roche Ltd

Novartis

Lonza

GlaxoSmithKline PLC

Eli Lilly and Company

Johnson & Johnson Services Inc.

Merck KGaA

List of Tables

Table 1. Chronic Granulomatous Disease (CGD) Treatment Market Trends

Table 2. Chronic Granulomatous Disease (CGD) Treatment Market Drivers & Opportunity

Table 3. Chronic Granulomatous Disease (CGD) Treatment Market Challenges

Table 4. Chronic Granulomatous Disease (CGD) Treatment Market Restraints

Table 5. Global Chronic Granulomatous Disease (CGD) Treatment Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Chronic Granulomatous Disease (CGD) Treatment Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Chronic Granulomatous Disease (CGD) Treatment Product Type

Table 9. Key Companies Time to Begin Mass Production of Chronic Granulomatous Disease (CGD) Treatment

Table 10. Global Chronic Granulomatous Disease (CGD) Treatment Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Treatment as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Chronic Granulomatous Disease (CGD) Treatment Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Chronic Granulomatous Disease (CGD) Treatment Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Chronic Granulomatous Disease (CGD) Treatment Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Chronic Granulomatous Disease (CGD) Treatment Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region (2019-2024) & (%)

Table 27. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Chronic Granulomatous Disease (CGD) Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2025-2030) & (US$ Million)

Table 31. Clinigen Group plc Basic Information List

Table 32. Clinigen Group plc Description and Business Overview

Table 33. Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 34. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Clinigen Group plc (2019-2024)

Table 35. Clinigen Group plc Recent Developments

Table 36. Orchard Therapeutics plc2032 Basic Information List

Table 37. Orchard Therapeutics plc2032 Description and Business Overview

Table 38. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 39. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Orchard Therapeutics plc2032 (2019-2024)

Table 40. Orchard Therapeutics plc2032 Recent Developments

Table 41. Horizon Therapeutics plc Basic Information List

Table 42. Horizon Therapeutics plc Description and Business Overview

Table 43. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 44. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Horizon Therapeutics plc (2019-2024)

Table 45. Horizon Therapeutics plc Recent Developments

Table 46. ViroMed. Co. Ltd Basic Information List

Table 47. ViroMed. Co. Ltd Description and Business Overview

Table 48. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 49. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of ViroMed. Co. Ltd (2019-2024)

Table 50. ViroMed. Co. Ltd Recent Developments

Table 51. Bellicum Pharmaceuticals, Inc Basic Information List

Table 52. Bellicum Pharmaceuticals, Inc Description and Business Overview

Table 53. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 54. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Bellicum Pharmaceuticals, Inc (2019-2024)

Table 55. Bellicum Pharmaceuticals, Inc Recent Developments

Table 56. Pfizer Inc Basic Information List

Table 57. Pfizer Inc Description and Business Overview

Table 58. Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 59. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Pfizer Inc (2019-2024)

Table 60. Pfizer Inc Recent Developments

Table 61. Hoffmann-La Roche Ltd Basic Information List

Table 62. Hoffmann-La Roche Ltd Description and Business Overview

Table 63. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 64. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Hoffmann-La Roche Ltd (2019-2024)

Table 65. Hoffmann-La Roche Ltd Recent Developments

Table 66. Novartis AG Basic Information List

Table 67. Novartis AG Description and Business Overview

Table 68. Novartis AG Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 69. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Novartis AG (2019-2024)

Table 70. Novartis AG Recent Developments

Table 71. Lonza Basic Information List

Table 72. Lonza Description and Business Overview

Table 73. Lonza Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 74. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Lonza (2019-2024)

Table 75. Lonza Recent Developments

Table 76. GlaxoSmithKline plc Basic Information List

Table 77. GlaxoSmithKline plc Description and Business Overview

Table 78. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 79. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of GlaxoSmithKline plc (2019-2024)

Table 80. GlaxoSmithKline plc Recent Developments

Table 81. Eli Lilly and Company Basic Information List

Table 82. Eli Lilly and Company Description and Business Overview

Table 83. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 84. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Eli Lilly and Company (2019-2024)

Table 85. Eli Lilly and Company Recent Developments

Table 86. Johnson & Johnson Services, Inc Basic Information List

Table 87. Johnson & Johnson Services, Inc Description and Business Overview

Table 88. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 89. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Johnson & Johnson Services, Inc (2019-2024)

Table 90. Johnson & Johnson Services, Inc Recent Developments

Table 91. Merck KGaA Basic Information List

Table 92. Merck KGaA Description and Business Overview

Table 93. Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Products, Services and Solutions

Table 94. Revenue (US$ Million) in Chronic Granulomatous Disease (CGD) Treatment Business of Merck KGaA (2019-2024)

Table 95. Merck KGaA Recent Developments

Table 96. Key Raw Materials Lists

Table 97. Raw Materials Key Suppliers Lists

Table 98. Chronic Granulomatous Disease (CGD) Treatment Downstream Customers

Table 99. Chronic Granulomatous Disease (CGD) Treatment Distributors List

Table 100. Research Programs/Design for This Report

Table 101. Key Data Information from Secondary Sources

Table 102. Key Data Information from Primary Sources

Table 103. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Chronic Granulomatous Disease (CGD) Treatment Product Picture

Figure 2. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 4. Chronic Granulomatous Disease (CGD) Treatment Report Years Considered

Figure 5. Global Chronic Granulomatous Disease (CGD) Treatment Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Chronic Granulomatous Disease (CGD) Treatment Revenue in 2023

Figure 7. Chronic Granulomatous Disease (CGD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. X-Linked Chronic Granulomatous Disease Picture

Figure 9. Autosomal Recessive Chronic Granulomatous Disease Picture

Figure 10. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Neutrophil Function Tests

Figure 13. Product Picture of Genetic Testing

Figure 14. Product Picture of Prenatal Testing

Figure 15. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Chronic Granulomatous Disease (CGD) Treatment Sales Value Market Share by Application, 2023 & 2030

Figure 17. North America Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 18. North America Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 19. Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 20. Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 21. Asia Pacific Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 22. Asia Pacific Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 23. South America Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 24. South America Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 25. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 26. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 27. Key Countries/Regions Chronic Granulomatous Disease (CGD) Treatment Sales Value (%), (2019-2030)

Figure 28. United States Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 29. United States Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 30. United States Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 31. Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 32. Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 33. Europe Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 34. China Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 35. China Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 36. China Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 37. Japan Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 38. Japan Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 39. Japan Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 40. South Korea Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 41. South Korea Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 42. South Korea Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 43. Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 45. Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 46. India Chronic Granulomatous Disease (CGD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 47. India Chronic Granulomatous Disease (CGD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 48. India Chronic Granulomatous Disease (CGD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 49. Chronic Granulomatous Disease (CGD) Treatment Industrial Chain

Figure 50. Chronic Granulomatous Disease (CGD) Treatment Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Rosacea Therapeutics Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-11I14316

Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Palmer Hyperhidrosis Treatment Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-15M6064

Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Actinic Keratosis Therapeutics Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-35P13993

Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Dermatology Diagnostic Equipment Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-29K9641

Thu Dec 26 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions